ArticleJournal of cellular and molecular medicine2026
Deciphering Angiogenic Drivers in Hepatocellular Carcinoma: From Prognostic Signature Construction to Genistein-Mediated Inhibition.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor prognosis and a lack of reliable biomarkers. In this study, we integrated weighted gene co-expression network analysis, machine-learning-based prognosticmodelling, single-cell RNA sequencing, spatial transcriptomics, and molecular docking to identify angiogenesis-related drivers in HCC. SCAF1 was identified as a hub gene and was significantly upregulated in HCC tissues compared with normal liver tissues. High SCAF1 expression was closely associated with advanced clinicopathological features and unfavourable survival outcomes. The prognostic model constructed by machine learning showed robust predictive performance in both training and validation cohorts, and decision curve analysis supported its clinical utility. Single-cell and spatial transcriptomic analyses further suggested that SCAF1 was mainly associated with endothelial and immune-related features of the tumour microenvironment. Functional assays showed that SCAF1 knockdown suppressed HCC cell migration, invasion, VEGFA expression, and angiogenic capacity in vitro. Mechanistically, SCAF1 was negatively correlated with anti-angiogenic chemokines, including CCL19, CCL14, and CCL11, indicating a role in shaping a pro-angiogenic microenvironment. In addition, molecular docking identified genistein as a promising compound with stable binding to SCAF1. Experimental validation showed that genistein reduced SCAF1 and VEGFA expression and inhibited HCC cell proliferation, migration, invasion, and tube formation. Collectively, these findings suggest that SCAF1 is a novel prognostic and angiogenesis-related biomarker in HCC and a potential therapeutic target for genistein-based intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.